Shots:
- Senseonics has filed for the CE Mark Approval of its Eversense 365 CGM system. If approved, it will be distributed in the EU (Germany, Italy, Spain, Poland, Switzerland, Sweden, & Andorra) by Ascensia Diabetes Care (Senseonics’ commercial partner)
- Eversense offers longevity (1yr. vs 10-14 days for traditional CGMs), features a removable smart transmitter to reduce wastage, offers max. comfort with silicone adhesives, & requires 1 calibration/wk. to provide reliable alerts with high accuracy
- In Sep 2024, the US FDA granted 510(k) clearance to Eversense as an iCGM system, allowing its integration with compatible medical devices incl. insulin pumps as a part of automated insulin delivery (AID) system to address its limitations
Ref:Â Senseonics |Â Image:Â Senseonics
Related News:- Gyder Surgical Reports the US FDA’s 510(k) Clearance for Gyder Hip System
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
